Eversheds Sutherland has advised Sinclair Pharma plc (Sinclair) on its proposed cash acquisition by a subsidiary of China’s Huadong Medicine Co (Huadong) which values Sinclair at…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
